The Enduring Legacy of Al Yergey and the Award’s Significance
Al Yergey, a name synonymous with dedication and innovation in mass spectrometry, is remembered as an unsung hero of the field. His career was characterized by a steadfast commitment to both scientific excellence and the development of future generations of researchers. Established on the 50th anniversary of his ASMS membership and in the year of his passing, the Al Yergey Mass Spectrometry Scientist Award serves as a living tribute to his spirit. Yergey was known for his tireless commitment to "bringing people up with them," a philosophy that emphasized mentorship, collaboration, and the communal advancement of scientific knowledge. This ethos forms the bedrock of the award’s selection criteria, recognizing individuals who not only innovate but also actively contribute to the growth and success of their peers and proteges.
The American Society for Mass Spectrometry (ASMS) is the premier professional organization for mass spectrometrists globally, fostering scientific exchange and recognizing outstanding achievements. The Al Yergey Award, presented at the annual ASMS conference, holds significant prestige within the community. It underscores the importance of not just individual breakthroughs, but also the collaborative spirit and human element essential for sustained scientific progress. The 2026 recipients exemplify these dual qualities, having made profound scientific contributions while demonstrating a clear dedication to advancing the capabilities and accessibility of mass spectrometry for a broader scientific audience.
Daniel McClatchy: Illuminating Proteomic Dynamics in Neurological Research
Daniel McClatchy, a Senior Staff Scientist in the Yates lab at the Scripps Research Institute in La Jolla, California, USA, was recognized for his transformative work in quantitative method development, particularly for investigating neuroscience disease models. His innovations have provided researchers with unparalleled tools to observe the intricate and dynamic changes within proteomes, which is crucial for understanding complex neurological conditions and identifying potential therapeutic targets.
Pioneering the PALM Method for In Vivo Proteomics
A cornerstone of McClatchy’s recognition is his pioneering idea to label the proteomes of rodents in vivo and the subsequent development of the Pulse Azidohomoalanine Labeling in Mammals (PALM) method. PALM is a sophisticated technique building upon foundational work by Dave Tirrell and Erin Schuman at the California Institute of Technology, who developed non-canonical amino acids such as Azidohomoalanine (AHA) and the more recent Azidonorleucine (ANL). These modified amino acids serve as metabolic tags, allowing for specific labeling within living organisms.
In the PALM method, AHA is metabolically incorporated into newly synthesized proteins in place of methionine. This strategic substitution introduces an azide functional group into the proteome, which can then be selectively reacted with a biotin tag via "click chemistry." This ingenious approach enables the specific enrichment and isolation of newly synthesized proteins from the complex cellular environment. The significance of this lies in the fact that newly synthesized proteins represent the most dynamic and rapidly changing fraction of the proteome, making them critical indicators of cellular responses to stimuli, stress, or disease progression. By specifically targeting and analyzing these proteins, researchers can gain deeper insights into the earliest molecular events underlying various diseases, potentially leading to the identification of novel biomarkers and more effective therapeutic strategies.
McClatchy highlighted that PALM’s full potential is still being realized, especially with the advent of ANL, a cell-specific non-canonical amino acid. This specificity is a game-changer for neuroscience, enabling researchers to label and study the proteomes of particular cell types within the brain – a significant advance over the earlier AHA method which primarily provided a composite snapshot of the entire brain proteome. This precision is vital for dissecting the roles of specific neuronal or glial populations in neurodegenerative diseases like Alzheimer’s or Parkinson’s, or in psychiatric disorders.
Navigating Downstream Analysis in PALM Experiments
For researchers contemplating the use of PALM, McClatchy offers crucial advice centered on downstream analysis, outlining two primary approaches: protein enrichment or peptide enrichment. Historically, protein enrichment has been more common, involving click chemistry to attach biotin to the newly synthesized proteins, followed by pull-down using streptavidin beads. While effective, this method presents a challenge: after protein digestion and mass spectrometric analysis, the biotin tag is typically lost, raising concerns about potential non-specific binding of other proteins to the streptavidin beads, thus compromising the absolute certainty of identifying only newly synthesized proteins.
McClatchy’s lab introduced a significant refinement: performing protein digestion before enrichment. This strategy involves enriching peptides that specifically carry the biotin tag. The advantage is a 100% positive identification of newly synthesized proteins, as the presence of the biotin tag directly confirms the peptide’s origin from a metabolically labeled protein. However, this increased specificity comes with a trade-off in sensitivity. Relying on only one or two tagged peptides per protein means that the signal for individual proteins can be much weaker, making detection more challenging. McClatchy noted that his team is actively working on improving the sensitivity of this peptide-centric pipeline to maximize its utility, pushing the boundaries of what can be detected in complex biological samples.
Optimizing SILAM for Quantitative In Vivo Proteomics
Beyond PALM, Daniel McClatchy also played a critical role in optimizing and popularizing the Stable Isotope Labeling of Mammals (SILAM) workflow for quantitative in vivo proteomics. SILAM is an elegant quantitative technique where an entire mouse or rat proteome is metabolically labeled with heavy nitrogen-15 (N15). This is achieved by feeding the animals a specialized diet where spirulina, a blue-green algae, serves as the sole protein source and is 100% labeled with N15. While SILAM was initially developed in John Yates’s lab by Christine Wu and Mike MacCoss at the University of Washington, McClatchy stepped in to refine its practical application, particularly in the context of disease models.
A key challenge with SILAM is achieving complete N15 labeling, which can be a time-consuming process, often taking months or even requiring labeling across generations (labeling the mother and then her pups). McClatchy’s work was instrumental in systematically determining the precise labeling kinetics in different tissues and under various physiological conditions, providing critical guidelines for researchers to ensure optimal experimental design and reliable quantification.
McClatchy emphasized the versatility of SILAM, noting its evolving applications. Initially, it was primarily used for quantifying proteomic differences between diseased and healthy states. However, researchers are now leveraging SILAM to investigate protein turnover rates and to identify long-lived proteins. In these experiments, animals are labeled with N15, then switched back to a regular, unlabeled diet, allowing scientists to monitor the degradation rates of proteins over time. This offers profound insights into protein homeostasis, aging, and disease pathogenesis, providing a dynamic view of the proteome that static measurements cannot capture.
His advice for new SILAM users highlights two critical considerations. First, the downstream bioinformatics analysis required to accurately calculate the N15 incorporation in each protein is highly complex. Researchers must ensure they have access to robust bioinformatic tools and expertise to handle the intricate data processing, which often involves sophisticated algorithms to deconvolve isotopic patterns. Second, the incorporation of heavy stable isotopes, while generally well-tolerated, can subtly alter the proteome. While not drastic, these changes necessitate careful experimental controls. McClatchy suggests the routine use of internal standards to account for any isotopic effects, ensuring the validity and comparability of results in quantitative studies.
For McClatchy, receiving the Al Yergey MS Scientist Award is a significant honor. He expressed deep respect for the caliber of previous and current awardees, describing them as "really amazing scientists who have accomplished a lot." To be associated with such a distinguished group, he stated, is a profound recognition of his contributions to the field and a testament to the collaborative spirit that Al Yergey championed.
Michael Senko: Driving Innovation in Mass Spectrometry Instrumentation
Michael Senko, a Principal Scientist at Thermo Fisher Scientific in Massachusetts, USA, has dedicated over three decades to advancing mass spectrometry instrumentation. His work has been fundamental in developing technologies that serve proteomics, biopharmaceutical characterization, and broader life science research. Senko’s relentless focus on enhancing instrument performance and enabling new analytical capabilities has empowered scientists to tackle increasingly complex biological questions with unprecedented precision and speed.
Senko expressed immense gratitude for the Al Yergey MS Scientist Award, viewing it as a testament to a career dedicated to pushing the boundaries of MS instrumentation. His contributions range from the pioneering development of benchtop ion traps to the creation of high-performance hybrid mass spectrometers, which have achieved industry-leading resolution and expanded the speed, sensitivity, flexibility, and analytical power of MS. Crucially, Senko underscored that these accomplishments are not solitary efforts but are the direct result of collaborating with and building "exceptional teams of scientists and engineers whose creativity, dedication, and hard work made those advances possible." This emphasis on teamwork and collective effort strongly echoes Al Yergey’s own ethos of mentorship and collaborative advancement, highlighting the importance of fostering talent and shared goals.
Revolutionizing Mass Spectrometry with LTQ and Tribrid Architectures
Among his many innovations, Senko highlighted two achievements of which he is particularly proud. The first is his role in developing the original Linear Trap Quadrupole (LTQ). This instrument marked a significant leap forward by simultaneously improving sensitivity, dynamic range, and scan speed compared to earlier 3D ion traps. This combination dramatically expanded the capabilities of tandem mass spectrometry (MS/MS), making it possible to identify and characterize proteins with much greater efficiency and depth, thereby laying the groundwork for many subsequent advancements in proteomics, including the large-scale protein identification projects that define modern proteomic research.
His second source of pride is the creation of the Tribrid architecture. This revolutionary design integrated a quadrupole, an ion trap, and an Orbitrap mass analyzer into a single instrument. This unique configuration provides scientists with unparalleled flexibility, allowing them to select the optimal combination of mass analysis and fragmentation methods for each specific experiment. The Tribrid platform has become a
